Select Publications
Journal articles
2006, 'The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: Final results from a randomized clinical trial (Pulse)', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 42, pp. 192 - 202
,2005, 'A new variant cytotoxic T lymphocyte escape mutation in HLA-B27-positive individuals infected with HIV type 1', AIDS Research and Human Retroviruses, 21, pp. 395 - 397
,2005, 'Early proliferation of CCR5(+) CD38(+++) antigen-specific CD4(+) Th1 effector cells during primary HIV-1 infection', Blood, 106, pp. 1660 - 1667
,2005, 'Impaired mitochondrial function induced by NRTIs is only detectable in the monocyte (CD14(+)) subset of human PBMC', Antiviral Therapy, 10, pp. L44 - L45
,2005, 'In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA', Journal of Infectious Diseases, 191, pp. 1686 - 1696
,2005, 'Methodological considerations in human studies of gene expression in HIV-associated lipodystrophy', Antiviral Therapy, 10, pp. M101 - M108
,2005, 'Nucleoside reverse transcriptase inhibitor effects on adipocyte mitochondrial DNA quantity and quality in vitro', Antiviral Therapy, 10, pp. L41 - L42
,2005, 'Prolonged transcriptional silencing and CpG methylation induced by siRNAs targeted to the HIV-1 promoter region.', Journal of RNAi and Gene Silencing, 1, pp. 66 - 78
,2005, 'Randomised, Placebo-Controlled, Phase 1/2a Evaluation of the Safety and Immunogenicity of Fowlpox Virus Expressing HIV gag-pol and Interferon-y in HIV-1 Infected Subjects', Human Vaccines, 1, pp. 232 - 238, http://www.landesbioscience.com/journals/vaccines/emeryHV1-6.pdf
,2005, 'The modern ART of HIV infection management: Towards a tailored approach to maximize CD4 T cell reconstitution', Clinical Infectious Diseases, 41, pp. 373 - 375
,2004, 'Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection', Blood, 103, pp. 2238 - 2247, http://dx.doi.org/10.1182/blood-2003-08-2765
,2004, 'Antiretroviral therapy-induced immune restoration in HIV infection: A double-edged sword?', Expert Review of Anti-Infective Therapy, 2, pp. 335 - 339, http://dx.doi.org/10.1586/14787210.2.3.335
,2004, 'Changes in nuclear gene expression resulting from NRTI-induced inhibition of mitochondrial transcription reveal links between mitochondrial dysfunction and lipid metabolism', Antiviral Therapy, 9, pp. L56 - L56
,2004, 'Frequent transmission of Cytotoxic-T-Lymphocyte escape mutants of human immunodeficiency virus type 1 in the highly HLA-A24-positive Japanese population', Journal of Virology, 78, pp. 8437 - 8445
,2004, 'Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term non-progressor and in CMV infection', Blood, 8, pp. 2765 - 2765
,2004, 'In vivo nucleoside reverse transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes independent to HIV infection', Antiviral Therapy, 9, pp. L11 - L11
,2004, 'Nucleoside reverse transcriptase inhibitors (NRTI) decrease adipocyte and monocyte mitochondrial (mt) messenger RNA transcription in the absence of changes in mtDNA or cell morphology', Antiviral Therapy, 9, pp. L56 - L57
,2004, 'Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy', Annals of Oncology, 15, pp. 324 - 329
,2003, 'Cytokine therapies in HIV-1 infection: Present and future', Expert Review of Anti-Infective Therapy, 1, pp. 83 - 96, http://dx.doi.org/10.1586/14787210.1.1.83
,2003, 'Cytokine therapies in HIV-1 infection: present and future', Expert Review of Anti-Infective Therapy, 1, pp. 89 - 102
,2003, 'First demonstration of a lack of viral sequence evolution in a nonprogressor, defining replication-incompetent HIV-1 infection', Virology, 312, pp. 135 - 135
,2003, 'Naive T cells maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty', Immunology and Cell Biology, 81, pp. 487 - 495
,2003, 'No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infection: 1992-2001', AIDS, 17, pp. 264 - 267
,2003, 'Polyclonal proliferation and apoptosis of CCR5+ T Lymphocytes during primary human immunodeficiency virus type 1 infection: regulation by interleukin (IL)-2, IL-15, and Bcl-2', Journal of Infectious Diseases, 187, pp. 1735 - 1735
,2003, 'Rates of transmission of antiretroviral drug resistant strains of HIV-1', Journal of Clinical Virology, 26, pp. 153 - 153
,2002, 'Structured treatment interruption and beyond', BIOFUTUR, pp. 52 - 58, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000180098300009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2002, 'Supervised or structured treatment interruption (STI) and beyond...', Biofutur, pp. 52 - 58
,2002, 'Characterization of CD4(+) CTLs ex vivo', Journal of Immunology, 168, pp. 5954 - 5958
,2002, 'Comprehensive analyses of a unique HIV-1-infected nonprogressor reveal a complex association of immunobiological mechanisms in the context of replication-incompetent infection', Virology, 304, pp. 246 - 264
,2002, 'Dyslipidemia due to retroviral protease inhibitors', Nature Medicine, 8, pp. 308 - 308, http://dx.doi.org/10.1038/nm0402-308a
,2002, 'Optimization of peptide linker length in production of MHC Class II/peptide tetrameric complexes increases yield, stability and allows identification of antigen specific CD4+ T cells in PBMC', European Journal of Immunology, 32, pp. 3366 - 3375
,2002, 'STI and beyond: the prospects of boosting anti-HIV immune responses', Trends in Immunology, 23, pp. 456 - 460
,2001, 'Effects of retroviral protease inhibitors on proteasome function and processing of HIV-derived MHC class I-restricted cytotoxic T lymphocyte epitopes', AIDS Research and Human Retroviruses, 17, pp. 1063 - 1066, http://dx.doi.org/10.1089/088922201300343744
,2001, 'Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses', Journal of Experimental Medicine, 193, pp. 375 - 385, http://dx.doi.org/10.1084/jem.193.3.375
,2001, 'Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine', AIDS Research and Human Retroviruses, 17, pp. 1293 - 1296, http://dx.doi.org/10.1089/088922201750461366
,2001, 'Relative significance of different pathways of immune reconstitution in HIV type 1 infection as estimated by mathematical modelling.', AIDS Research and Human Retroviruses, 17, pp. 147 - 159
,2000, 'Functions of tetramer-stained HIV-specific CD4+ and CD8+ T cells', Current Opinion in Immunology, 12, pp. 370 - 374, http://dx.doi.org/10.1016/S0952-7915(00)00102-3
,2000, 'Memory CD8+ T cells in HIV infection', Philosophical Transactions of the Royal Society B: Biological Sciences, 355, pp. 363 - 367, http://dx.doi.org/10.1098/rstb.2000.0575
,2000, 'Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes', Proceedings of the National Academy of Sciences of the United States of America, 97, pp. 3382 - 3387, http://dx.doi.org/10.1073/pnas.97.7.3382
,2000, 'Cytotoxic T lymphocyte responses to human immunodeficiency virus: Control and escape', Stem Cells, 18, pp. 230 - 244, http://dx.doi.org/10.1634/stemcells.18-4-230
,2000, 'Highly active antiretroviral therapy for primary HIV-1 infection preserves immune function of virus-specific T lymphocytes', Quarterly Journal of Medicine, 93, pp. 769 - 769
,2000, 'Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection', AIDS, 14, pp. 2543 - 2551
,1999, 'The arrival of HLA class II tetramers', Journal of Clinical Investigation, 104, pp. 1669 - 1770, http://dx.doi.org/10.1172/jci8943
,1999, 'Effect of protease therapy on cytokine secretion by peripheral blood mononuclear cells (PBMC) from HIV-infected subjects', Clinical and Experimental Immunology, 115, pp. 147 - 152
,1999, 'Potent antiretroviral therapy of primary HIV-1 infection: partial normalisation of T lympho-cyte subsets and limited reduction of proviral DNA despite clearance of plasma viremia.', Journal of Infectious Diseases, 180, pp. 320 - 329
,1999, 'Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific CTL activity in asymptomatic HIV infected individuals.', AIDS Research and Human Retroviruses, 15, pp. 105 - 113
,1998, 'Oligoclonal expansions of CD8+ T cells in chronic HIV infection are antigen specific', Journal of Experimental Medicine, 188, pp. 785 - 790, http://dx.doi.org/10.1084/jem.188.4.785
,1998, 'A model of primary HIV-1 infection', Mathematical Biosciences, 154, pp. 57 - 85
,1998, 'Can Antiretroviral Therapy 'treat' Opportunistic Infections in Patients with HIV Infection', HIV Advances in Research and Therapy, 8
,1998, 'Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens', Clinical and Experimental Immunology, 113, pp. 85 - 91
,